| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97a285d8ecd0184a7e5d89a1e4e07997 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 |
| filingDate |
1981-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1982-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
GB-2078518-A |
| titleOfInvention |
Sustained release theophylline tablet having reduced bulk |
| abstract |
Non-disintegrating tablets containing at least 95% by weight theophylline having a pair of opposing substantially planar surfaces and a very thin cross-section (i.e. 2.03-3.05 mm) have a high bioavailability on ingestion and a relatively steady release rate permitting a 12 hr. dosing interval for maintenance of non-toxic therapeutic blood theophylline concentrations. Excipients or tableting aids are not required, but trace amounts of a tableting lubricant are preferably included to facilitate continuous large scale production. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8402843-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4753945-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4503031-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0239481-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2143734-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4547358-A |
| priorityDate |
1980-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |